Loading…
Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis
Saved in:
| Published in: | Blood 2009-10, Vol.114 (16), p.3502-3503 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c2056-16e6bf8fd0b17932ff12501e5d3dc4c5c2b9235031c1ae4a3d87d335031ab4653 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c2056-16e6bf8fd0b17932ff12501e5d3dc4c5c2b9235031c1ae4a3d87d335031ab4653 |
| container_end_page | 3503 |
| container_issue | 16 |
| container_start_page | 3502 |
| container_title | Blood |
| container_volume | 114 |
| creator | Pardanani, Animesh Tefferi, Ayalew Litzow, Mark R. Zent, Clive Hogan, William J. McClure, Rebecca F. Viswanatha, David |
| description | |
| doi_str_mv | 10.1182/blood-2009-07-234666 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2009_07_234666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712036780X</els_id><sourcerecordid>19833856</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2056-16e6bf8fd0b17932ff12501e5d3dc4c5c2b9235031c1ae4a3d87d335031ab4653</originalsourceid><addsrcrecordid>eNp9kN1q3DAQhUVpaLZp36AUPUDUjiRLtntRSJb-wUIgtNdClsZdNbZkJG-KX6FPHW82pXe9GphzzszhI-QNh3ecN-J9N6TkmQBoGdRMyEpr_YxsuBINAxDwnGwAQLOqrfk5eVnKLwBeSaFekHPeNlI2Sm_In-0-pxgcHRccUvB0wMMdjsHS32He04m3cL29ZVfXuw90ynhvB4wOL-mY8rRPQ_q5XNJ5yamEiPQuRFuQhrgPXZhTphnLlGJZ_Tb6v7JPow2RjofZziHFVbLDUkJ5Rc56OxR8_TQvyI_Pn75vv7LdzZdv26sdcwKUZlyj7vqm99DxupWi77lQwFF56V3llBNdK6QCyR23WFnpm9rLx4XtKq3kBalOd91au2TszZTDaPNiOJgjWvOI1hzRGqjNCe0ae3uKTYduRP8v9MRyNXw8GXAtfx8wm-LCkZYPGd1sfAr___AAyUqMig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis</title><source>ScienceDirect®</source><creator>Pardanani, Animesh ; Tefferi, Ayalew ; Litzow, Mark R. ; Zent, Clive ; Hogan, William J. ; McClure, Rebecca F. ; Viswanatha, David</creator><creatorcontrib>Pardanani, Animesh ; Tefferi, Ayalew ; Litzow, Mark R. ; Zent, Clive ; Hogan, William J. ; McClure, Rebecca F. ; Viswanatha, David</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2009-07-234666</identifier><identifier>PMID: 19833856</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Cohort Studies ; DNA Mutational Analysis ; Fusion Proteins, bcr-abl - biosynthesis ; Fusion Proteins, bcr-abl - genetics ; Gene Expression Regulation, Leukemic - drug effects ; Gene Expression Regulation, Leukemic - genetics ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism ; Male ; Middle Aged ; Mutation ; Protein Kinase Inhibitors - administration & dosage ; Protein Structure, Tertiary ; Protein-Tyrosine Kinases - biosynthesis ; Protein-Tyrosine Kinases - genetics</subject><ispartof>Blood, 2009-10, Vol.114 (16), p.3502-3503</ispartof><rights>2009 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2056-16e6bf8fd0b17932ff12501e5d3dc4c5c2b9235031c1ae4a3d87d335031ab4653</citedby><cites>FETCH-LOGICAL-c2056-16e6bf8fd0b17932ff12501e5d3dc4c5c2b9235031c1ae4a3d87d335031ab4653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S000649712036780X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27901,27902,45756</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19833856$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pardanani, Animesh</creatorcontrib><creatorcontrib>Tefferi, Ayalew</creatorcontrib><creatorcontrib>Litzow, Mark R.</creatorcontrib><creatorcontrib>Zent, Clive</creatorcontrib><creatorcontrib>Hogan, William J.</creatorcontrib><creatorcontrib>McClure, Rebecca F.</creatorcontrib><creatorcontrib>Viswanatha, David</creatorcontrib><title>Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis</title><title>Blood</title><addtitle>Blood</addtitle><subject>Aged</subject><subject>Cohort Studies</subject><subject>DNA Mutational Analysis</subject><subject>Fusion Proteins, bcr-abl - biosynthesis</subject><subject>Fusion Proteins, bcr-abl - genetics</subject><subject>Gene Expression Regulation, Leukemic - drug effects</subject><subject>Gene Expression Regulation, Leukemic - genetics</subject><subject>Humans</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Structure, Tertiary</subject><subject>Protein-Tyrosine Kinases - biosynthesis</subject><subject>Protein-Tyrosine Kinases - genetics</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9kN1q3DAQhUVpaLZp36AUPUDUjiRLtntRSJb-wUIgtNdClsZdNbZkJG-KX6FPHW82pXe9GphzzszhI-QNh3ecN-J9N6TkmQBoGdRMyEpr_YxsuBINAxDwnGwAQLOqrfk5eVnKLwBeSaFekHPeNlI2Sm_In-0-pxgcHRccUvB0wMMdjsHS32He04m3cL29ZVfXuw90ynhvB4wOL-mY8rRPQ_q5XNJ5yamEiPQuRFuQhrgPXZhTphnLlGJZ_Tb6v7JPow2RjofZziHFVbLDUkJ5Rc56OxR8_TQvyI_Pn75vv7LdzZdv26sdcwKUZlyj7vqm99DxupWi77lQwFF56V3llBNdK6QCyR23WFnpm9rLx4XtKq3kBalOd91au2TszZTDaPNiOJgjWvOI1hzRGqjNCe0ae3uKTYduRP8v9MRyNXw8GXAtfx8wm-LCkZYPGd1sfAr___AAyUqMig</recordid><startdate>20091015</startdate><enddate>20091015</enddate><creator>Pardanani, Animesh</creator><creator>Tefferi, Ayalew</creator><creator>Litzow, Mark R.</creator><creator>Zent, Clive</creator><creator>Hogan, William J.</creator><creator>McClure, Rebecca F.</creator><creator>Viswanatha, David</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20091015</creationdate><title>Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis</title><author>Pardanani, Animesh ; Tefferi, Ayalew ; Litzow, Mark R. ; Zent, Clive ; Hogan, William J. ; McClure, Rebecca F. ; Viswanatha, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2056-16e6bf8fd0b17932ff12501e5d3dc4c5c2b9235031c1ae4a3d87d335031ab4653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Cohort Studies</topic><topic>DNA Mutational Analysis</topic><topic>Fusion Proteins, bcr-abl - biosynthesis</topic><topic>Fusion Proteins, bcr-abl - genetics</topic><topic>Gene Expression Regulation, Leukemic - drug effects</topic><topic>Gene Expression Regulation, Leukemic - genetics</topic><topic>Humans</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Structure, Tertiary</topic><topic>Protein-Tyrosine Kinases - biosynthesis</topic><topic>Protein-Tyrosine Kinases - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pardanani, Animesh</creatorcontrib><creatorcontrib>Tefferi, Ayalew</creatorcontrib><creatorcontrib>Litzow, Mark R.</creatorcontrib><creatorcontrib>Zent, Clive</creatorcontrib><creatorcontrib>Hogan, William J.</creatorcontrib><creatorcontrib>McClure, Rebecca F.</creatorcontrib><creatorcontrib>Viswanatha, David</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pardanani, Animesh</au><au>Tefferi, Ayalew</au><au>Litzow, Mark R.</au><au>Zent, Clive</au><au>Hogan, William J.</au><au>McClure, Rebecca F.</au><au>Viswanatha, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2009-10-15</date><risdate>2009</risdate><volume>114</volume><issue>16</issue><spage>3502</spage><epage>3503</epage><pages>3502-3503</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19833856</pmid><doi>10.1182/blood-2009-07-234666</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2009-10, Vol.114 (16), p.3502-3503 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2009_07_234666 |
| source | ScienceDirect® |
| subjects | Aged Cohort Studies DNA Mutational Analysis Fusion Proteins, bcr-abl - biosynthesis Fusion Proteins, bcr-abl - genetics Gene Expression Regulation, Leukemic - drug effects Gene Expression Regulation, Leukemic - genetics Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Male Middle Aged Mutation Protein Kinase Inhibitors - administration & dosage Protein Structure, Tertiary Protein-Tyrosine Kinases - biosynthesis Protein-Tyrosine Kinases - genetics |
| title | Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A22%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20myeloid%20leukemia%20with%20p190BCR-ABL:%20prevalence,%20morphology,%20tyrosine%20kinase%20inhibitor%20response,%20and%20kinase%20domain%20mutation%20analysis&rft.jtitle=Blood&rft.au=Pardanani,%20Animesh&rft.date=2009-10-15&rft.volume=114&rft.issue=16&rft.spage=3502&rft.epage=3503&rft.pages=3502-3503&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2009-07-234666&rft_dat=%3Cpubmed_cross%3E19833856%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2056-16e6bf8fd0b17932ff12501e5d3dc4c5c2b9235031c1ae4a3d87d335031ab4653%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/19833856&rfr_iscdi=true |